secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001214659-24-008914
Event type: other_material
Sentiment:  positive
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro stockholders approve $6 million Series B transaction with Ault Lending
--------------------------------------------------------------------------------

- Stockholders approved issuance of up to 6,000 shares of Series B convertible preferred stock and warrants for 6,000,000 common shares at $6 million total.
- Proposal passed with 2,787,961 votes for, 208,270 against, and 49,368 abstentions at the May 13, 2024 adjourned annual meeting.
- The transaction is with Ault Lending, LLC per Securities Purchase Agreement dated January 31, 2024.
- The approval allows compliance with Nasdaq Listing Rule 5635 for the Series B Transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008914/0001214659-24-008914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008914/o5132458k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-008914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer